Genelux (NASDAQ:GNLX) Cut to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of Genelux (NASDAQ:GNLX) from a sell rating to a strong sell rating in a research report sent to investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Genelux in a report on Friday, July 17th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Genelux Stock Down 1.5%

Shares of Genelux stock opened at $2.70 on Friday. The company has a market cap of $121.07 million, a PE ratio of -3.14 and a beta of 0.60. The business has a 50 day moving average of $2.89 and a 200 day moving average of $2.77. Genelux has a 52 week low of $2.29 and a 52 week high of $8.53.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). On average, research analysts anticipate that Genelux will post -0.8 earnings per share for the current year.

Insider Activity at Genelux

In other news, Director John W. Smither sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $2.91, for a total value of $34,920.00. Following the sale, the director directly owned 91,403 shares of the company’s stock, valued at $265,982.73. The trade was a 11.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director John Thomas sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $2.98, for a total value of $29,800.00. Following the completion of the sale, the director owned 472,784 shares in the company, valued at $1,408,896.32. The trade was a 2.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,868 shares of company stock valued at $76,120 over the last quarter. Company insiders own 7.50% of the company’s stock.

Institutional Investors Weigh In On Genelux

Several hedge funds have recently added to or reduced their stakes in GNLX. Creative Planning grew its stake in shares of Genelux by 4.7% in the third quarter. Creative Planning now owns 46,108 shares of the company’s stock worth $194,000 after acquiring an additional 2,084 shares during the last quarter. Raymond James Financial Inc. raised its position in shares of Genelux by 22.6% in the 2nd quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock worth $83,000 after purchasing an additional 5,333 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Genelux by 1.8% in the 2nd quarter. Geode Capital Management LLC now owns 318,825 shares of the company’s stock worth $915,000 after purchasing an additional 5,596 shares during the last quarter. Jefferies Financial Group Inc. bought a new position in Genelux in the 4th quarter worth about $48,000. Finally, GSA Capital Partners LLP bought a new position in Genelux in the 2nd quarter worth about $35,000. 37.33% of the stock is owned by institutional investors.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.